With a long history of development and manufacturing of generic products, Pharmathen has emerged as one of the largest generic development companies in Europe with a development pipeline of ten generic molecules a year.

Today, Pharmathen’s in-house development products are registered in all major EU markets and licensed out to major pharmaceutical companies in Europe, Canada, Australia, South Africa and the United States. Our competitive edge is characterized by cost efficient development and production, creative marketing and added value customer service.

Through strategic partnerships, including but not limited to Licensing or distribution agreements, our international activities have expanded to more than 80 countries worldwide including all the E.U. states, and this has been accomplished through the talent and dedication of our employees who align their goals with the needs of our customers and partners, as well as the needs and requirements of each market.

In parallel, Pharmathen is investing on the introduction of value added health care products in the local market. With an extensive product portfolio and an experienced sales force of over 120 specialists and medical representatives, Pharmathen has become a leader in certain therapeutic areas and one of the fastest growing pharmaceutical companies in Greece.

General

History

Mission

Structure

Personnel